Skip to content

The efficacy of supportive treatment in IgA nephropathy

Supportive management of IgA nephropathy: a prospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011414
Enrollment
100
Registered
2018-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with biopsy proven primary IgA nephropathy with proteinuria equal to or more than 1g/day and eGFR more than 30ml/min/1.73m2

Interventions

None listed

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Biopsy proven primary IgA nephropathy with proteinuria>=1g/day

Exclusion criteria

Exclusion criteria: 1.Lack of informed consent 2.eGFR 3.Presence of crescents on kidney biopsy 4.History of immunosuppressive therapy in last 6 months for more than 2 weeks 5. Past history of use of Angiotensin converting enzyme inhibitors(ACEi) or Angiotensin receptor blockers(ARBS) in the previous 6 months 5.Patients with a second coexisting disease on kidney biopsy like diabetic nephropathy 6.Secondary causes of IgA nephropathy like chronic liver disease, Henoch Schonlein Purpura 7.Patient who is pregnant or breast feeding at the time of recruitment

Design outcomes

Primary

MeasureTime frame
Achieving complete or partial remission: Complete remission: Proteinuria les than 0.5g/day with no greater than 25% decline in eGFR. Partial remission:Atleast 50% decline in proteinuria from the baseline with no greater than 25% decline in eGFR No response: Less than 50% reduction, unchanged/increasing 24 hour proteinuria from baseline and/or 50% or more decline in eGFR or progression to end stage renal disease which cannot be attributed to any other cause. Timepoint: Patients will be followed up monthly for 6months. Those who achieve the primary outcome will be then followed up till 5 years to look for sustained response

Secondary

MeasureTime frame
Renal deterioration:50% or more decline in eGFR or progression to end stage renal disease which cannot be attributed to any other cause. Timepoint: Monthly follow up till 6 months

Countries

India

Contacts

Public ContactSoumita Bagchi

All India Institute of Medical Sciences

soumita_bagchi@yahoo.co.in9871911744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026